FDA approves new treatment for most common type of skin cancer

January 30, 2012, 10:58 am by FDA US Food & Drug Administration

Today, Erivedge (vismodegib) was approved by the U.S. Food and Drug Administration to treat adult patients with basal cell carcinoma, the most common type of skin cancer. The drug is intended for use in patients with locally advanced basal cell cancer who are not candidates for surgery or radiation and for patients whose cancer has spread to other parts of the body (metastatic).

Read the full article

More from FDA US Food & Drug Administration

FDA approves generic versions of blood thinner Plavix
FDA US Food & Drug Administration : May 17, 2012, 2:04 am
The U.S. Food and Drug Administration today approved generic versions of the blood thinning drug Plavix (clopidogrel bisulfate), which helps reduce the risk of heart attack and stroke by making it less

FDA expands use for FilmArray Respiratory Panel
FDA US Food & Drug Administration : May 15, 2012, 1:29 am
The U.S. Food and Drug Administration today expanded the use for the FilmArray Respiratory Panel, the first test that can simultaneously detect both viral and bacterial causes of respiratory infection from a

FDA issues alert on potential dangers of unproven treatment for multiple sclerosis
FDA US Food & Drug Administration : May 10, 2012, 8:58 am
The U.S. Food and Drug Administration is alerting health care professionals and patients about injuries and death associated with the use of an experimental procedure sometimes called “liberation therapy” or the “liberation

FDA proposal aims to help reduce unnecessary radiation exposure for children
FDA US Food & Drug Administration : May 9, 2012, 9:00 am
Today, the U.S. Food and Drug Administration announced that it is seeking public comment on a proposal encouraging manufacturers to consider the safety of children in the design of new X-ray imaging

FDA issues final rule on sterility testing of biological products
FDA US Food & Drug Administration : May 3, 2012, 1:52 am
The U.S. Food and Drug Administration issued its final rule on sterility testing, amending the requirements for most licensed biological products.